Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma

NCT00212043 ↗

Phase 2 Completed 74 enrolled National University Hospital, Singapore Eli Lilly and Company · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer

Timeline

Start: 2000-07
Primary completion: —
Completion: 2004-02

Publications

Tham LS, Wang LZ, Soo RA, Lee HS, Lee SC, Goh BC, Holford NH. Does saturable formation of gemcitabine triphosphate occur in patients? Cancer Chemother Pharmacol. 2008 Dec;63(1):55-64. doi: 10.1007/s00280-008-0707-9. Epub 2008 Feb 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	10 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Carboplatin	Small molecule	5 unknown	—

Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma

Summary

Timeline

Publications

Drugs

Indications